Startek (SRT) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Startek in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRT shares.
View SRT analyst ratings or view top-rated stocks.

2 equities research analysts have issued twelve-month target prices for Startek's shares. Their SRT share price forecasts range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 72.4% from the stock's current price.
View analysts price targets for SRT or view top-rated stocks among Wall Street analysts.

Startek's stock was trading at $3.75 on January 1st, 2023. Since then, SRT shares have decreased by 22.7% and is now trading at $2.90.
View the best growth stocks for 2023 here.

Startek saw a increase in short interest in April. As of April 30th, there was short interest totaling 17,200 shares, an increase of 12.4% from the April 15th total of 15,300 shares. Based on an average daily volume of 27,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the company's stock are sold short.
View Startek's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SRT earnings forecast.

Startek, Inc. (NYSE:SRT) posted its quarterly earnings data on Monday, March, 27th. The business services provider reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.19. The business services provider had revenue of $92.96 million for the quarter, compared to analyst estimates of $169.88 million. Startek had a negative net margin of 0.37% and a positive trailing twelve-month return on equity of 9.02%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Startek investors own include Amicus Therapeutics (FOLD), KeyCorp (KEY), SentinelOne (S), Vishay Intertechnology (VSH), Huntington Bancshares (HBAN), Kindred Biosciences (KIN), Mitek Systems (MITK), People's United Financial (PBCT), Pfizer (PFE) and

Startek trades on the New York Stock Exchange (NYSE) under the ticker symbol "SRT."

Startek's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.36%), Geode Capital Management LLC (0.13%), Dimensional Fund Advisors LP (0.12%), Seizert Capital Partners LLC (0.11%), O Shaughnessy Asset Management LLC (0.09%) and Jane Street Group LLC (0.06%). Insiders that own company stock include Albert Aboody, Anupam Pahuja, Aparup Sengupta, Csp Management Ltd, Mukesh Sharda and Sudip Banerjee.
View institutional ownership trends.

Shares of SRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRT stock can currently be purchased for approximately $2.90.

Startek (NYSE:SRT) has a market capitalization of $116.93 million and generates $385.07 million in revenue each year. The business services provider earns $-2,260,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

The company employs 33,000 workers across the globe.

Startek's mailing address is 6200 SOUTH SYRACUSE WAY SUITE 485, GREENWOOD VILLAGE CO, 80111. The official website for the company is www.startek.com. The business services provider can be reached via phone at (303) 262-4500, via email at investor@startek.com, or via fax at 302-655-5049.